PRIOR AUTHORIZATION POLICY

POLICY: Antiseizure Medications – Rufinamide Prior Authorization Policy
- Banzel® (rufinamide tablets and oral suspension – Eisai, generic)

REVIEW DATE: 09/20/2023

INSTRUCTIONS FOR USE

THE FOLLOWING COVERAGE POLICY APPLIES TO HEALTH BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. CERTAIN CIGNA COMPANIES AND/OR LINES OF BUSINESS ONLY PROVIDE UTILIZATION REVIEW SERVICES TO CLIENTS AND DO NOT MAKE COVERAGE DETERMINATIONS. REFERENCES TO STANDARD BENEFIT PLAN LANGUAGE AND COVERAGE DETERMINATIONS DO NOT APPLY TO THOSE CLIENTS. COVERAGE POLICIES ARE INTENDED TO PROVIDE GUIDANCE IN INTERPRETING CERTAIN STANDARD BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. PLEASE NOTE, THE TERMS OF A CUSTOMER'S PARTICULAR BENEFIT PLAN DOCUMENT [GROUP SERVICE AGREEMENT, EVIDENCE OF COVERAGE, CERTIFICATE OF COVERAGE, SUMMARY PLAN DESCRIPTION (SPD) OR SIMILAR PLAN DOCUMENT] MAY DIFFER SIGNIFICANTLY FROM THE STANDARD BENEFIT PLANS UPON WHICH THESE COVERAGE POLICIES ARE BASED. FOR EXAMPLE, A CUSTOMER'S BENEFIT PLAN DOCUMENT MAY CONTAIN A SPECIFIC EXCLUSION RELATED TO A TOPIC ADDRESSED IN A COVERAGE POLICY. IN THE EVENT OF A CONFLICT, A CUSTOMER'S BENEFIT PLAN DOCUMENT ALWAYS SUPERSEDES THE INFORMATION IN THE COVERAGE POLICIES. IN THE ABSENCE OF A CONTROLLING FEDERAL OR STATE COVERAGE MANDATE, BENEFITS ARE ULTIMATELY DETERMINED BY THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT. COVERAGE DETERMINATIONS IN EACH SPECIFIC INSTANCE REQUIRE CONSIDERATION OF 1) THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT IN EFFECT ON THE DATE OF SERVICE; 2) ANY APPLICABLE LAWS/REGULATIONS; 3) ANY RELEVANT COLLATERAL SOURCE MATERIALS INCLUDING COVERAGE POLICIES AND; 4) THE SPECIFIC FACTS OF THE PARTICULAR SITUATION. COVERAGE POLICIES RELATE EXCLUSIVELY TO THE ADMINISTRATION OF HEALTH BENEFIT PLANS. COVERAGE POLICIES ARE NOT RECOMMENDATIONS FOR TREATMENT AND SHOULD NEVER BE USED AS TREATMENT GUIDELINES. IN CERTAIN MARKETS, DELEGATED VENDOR GUIDELINES MAY BE USED TO SUPPORT MEDICAL NECESSITY AND OTHER COVERAGE DETERMINATIONS.

CIGNA NATIONAL FORMULARY COVERAGE:

OVERVIEW

Rufinamide is indicated for adjunctive treatment of **seizures associated with Lennox-Gastaut syndrome** (LGS) in patients ≥ 1 year of age.[1]

Although rufinamide is only FDA-approved for use in LGS, clinical trial data indicate the drug may also be beneficial as adjunctive treatment of refractory focal epilepsy.[2] A review of six clinical trials found that rufinamide when used as an add-on treatment was effective in reducing seizure frequency in patients with drug-resistant focal epilepsy.

Disease Overview

LGS is a severe epileptic and developmental encephalopathy associated with a high rate of morbidity and mortality.[3,4] LGS most often begins between 3 years and 5 years of age and comprises approximately 3% to 4% of childhood epilepsies.[3-6] Affected children experience several different types of seizures, most commonly atonic seizures (sudden loss of muscle tone and limpness, also called drop seizures) and tonic seizures (increased muscle tone and muscle stiffness).[3,6] The three main forms of treatment of LGS are antiseizure medications (ASMs), dietary therapy (typically the ketogenic diet), and device/surgery (e.g., vagus nerve stimulation, corpus callosotomy).[6] None of the therapies are effective in all cases of LGS and the disorder has proven particularly resistant to most therapeutic options. The choice of

treatment should take into consideration the patient's age and other associated conditions.

Guidelines/Recommendations

Lennox-Gastaut syndrome: Currently, the FDA-approved drugs for this condition are Epidiolex® (cannabidiol oral solution), felbamate, lamotrigine, rufinamide, topiramate, and clobazam.[7] Despite the lack of level I or level II evidence, valproic acid remains a mainstay in treatment.[5,6,8] If valproic acid does not provide adequate seizure control, which is almost always the case, lamotrigine should be added as the first adjunctive therapy.[4] If the combination regimen of valproic acid and lamotrigine does not provide adequate control, then rufinamide should be initiated and either valproic acid or lamotrigine should be discontinued. If seizure control is still not achieved, the next adjunctive therapies to consider are topiramate, clobazam, and felbamate. There are limited evidence for the use of levetiracetam, zonisamide, and Fycompa® (perampanel tablets and oral suspension). Where possible, no more than two ASMs should be used concomitantly; use of multiple ASMs raise the risk of side effects and/or drug-drug interactions.

POLICY STATEMENT

Prior Authorization is recommended for prescription benefit coverage of rufinamide. All approvals are provided for the duration noted below. Because of the specialized skills required for evaluation and diagnosis of patients treated with rufinamide as well as the monitoring required for adverse events and long-term efficacy, initial approval requires rufinamide to be prescribed by, or in consultation with, a physician who specializes in the condition being treated.

Banzel® (rufinamide tablets and oral suspension – Eisai, generic) is(are) covered as medically necessary when the following criteria is(are) met for fda-approved indication(s) or other uses with supportive evidence (if applicable):

FDA-Approved Indication

1. **Lennox-Gastaut Syndrome.** Approve for 1 year if the patient meets ONE of the following (A or B):
   - **A)** Initial Therapy. Approve if the patient meets the following (i, ii, and iii):
     - **i.** Patient is ≥ 1 year of age; AND
     - **ii.** Patient has tried and/or is concomitantly receiving at least two other antiseizure medications; AND
       Note: Examples of antiseizure medications include valproic acid, gabapentin, phenytoin, carbamazepine, oxcarbazepine, lacosamide, levetiracetam, zonisamide, Fycompa (perampanel tablet or oral suspension), vigabatrin, lamotrigine, topiramate, clobazam, Diacomit (stiripentol capsules or oral suspension), Epidiolex (cannabidiol oral solution), and felbamate.

iii. The medication is prescribed by or in consultation with a neurologist.

B) Patient is Currently Receiving rufinamide. Approve if the patient is responding to therapy (e.g., reduced seizure severity, frequency, and/or duration) as determined by the prescriber.

Other Uses with Supportive Evidence

2. Treatment-Refractory Seizures/Epilepsy. Approve for 1 year if the patient meets ONE of the following (A or B):

A) Initial Therapy. Approve if the patient meets the following (i, ii, and iii):

i. Patient is ≥ 1 years of age; AND

ii. Patient has tried and/or is concomitantly receiving at least two other antiseizure medications; AND

Note: Examples of antiseizure medications include valproic acid, gabapentin, phenytoin, carbamazepine, oxcarbazepine, lacosamide, levetiracetam, zonisamide, Fycompa (perampanel tablet or oral suspension), vigabatrin, lamotrigine, topiramate, clobazam, Diacomit (stiripentol capsules or oral suspension), Epidiolex (cannabidiol oral solution), and felbamate.

iii. The medication is prescribed by or in consultation with a neurologist.

B) Patient is Currently Receiving rufinamide. Approve if the patient is responding to therapy (e.g., reduced seizure severity, frequency, and/or duration) as determined by the prescriber.

CONDITIONS NOT COVERED

Banzel® (rufinamide tablets and oral suspension – Eisai, generic) is(are) considered experimental, investigational or unproven for ANY other use(s).

REFERENCES

1. Banzel® tablets and oral suspension [prescribing information]. Woodcliff Lake, NJ: Eisai; November 2019.
2. Brigo F, Jones K, Eltze C, et al. Anti-seizure medications for Lennox-Gastaut syndrome. *Cochrane Database Syst Rev*. 2021;4(4):D003277.
3. Sirven JI, Shafer PO. Epilepsy Foundation – Lennox-Gastaut Syndrome. Updated February 2020. Available at: https://www.epilepsy.com/learn/types-epilepsy-syndromes/lennox-gastaut-syndrome-lgs. Accessed on September 14, 2023.
4. Cross JH, Auvin S, Falip M, et al. Expert opinion on the management of Lennox-Gastaut syndrome: treatment algorithms and practical considerations. *Front Neurol*. 2017;8:505.
5. Ostendorf AP, Ng YT. Treatment-resistant Lennox-Gastaut syndrome: therapeutic trends, challenges, and future directions. *Neuropsych Dis Treatment*. 2017;13:1131-1140.
6. Wheless JW. National Organization for Rare Diseases (NORD) – Lennox-Gastaut syndrome. Available at: https://rarediseases.org/rare-diseases/lennox-gastaut-syndrome/. Accessed on September 14, 2023.
7. Lennox-Gastaut Syndrome Foundation – Lennox-Gastaut Syndrome. Updated August 2022. Available at: https://www.lgsfoundation.org/about-lgs-2/how-is-lgs-treated/. Accessed on September 14, 2023.

8. Cherian KA. Lennox-Gastaut syndrome treatment & management. Updated August 6, 2020. Available at: https://emedicine.medscape.com/article/1176735-treatment. Accessed on September 14, 2023.

HISTORY

Type of Revision	Summary of Changes	Review Date
Annual Revision	No criteria changes.	09/14/2022
Annual Revision	The policy name was changed from Antiepileptics – Banzel Prior Authorization Policy to Antiseizure Medications – Rufinamide Prior Authorization Policy. Throughout the criteria, reference to antiepileptic medications was changed to antiseizure medications.	09/20/2023

"Cigna Companies" refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. © 2023 Cigna